COYA · Coya Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Dov A. Goldstein, MD Chief Financial Officer | ▲ Buy | Option Exercise | 27,557 Shares held | 8/18/2025 | View profile |
| Ann Lee Director | ▲ Buy | Open Market | 17,479 Shares held | 8/22/2023 | View profile |
| Arun Swaminathan Chief Executive Officer | ▲ Buy | Open Market | 10,000 Shares held | 11/13/2024 | View profile |
| Berman Howard Chief Executive Officer | ▲ Buy | Open Market | 10,000 Shares held | 1/3/2023 | View profile |
| Hepner Adrian Chief Medical Officer | ▲ Buy | Open Market | 10,000 Shares held | 1/3/2023 | View profile |
| Villalobos Anabella Director | ▲ Buy | Open Market | 10,000 Shares held | 1/3/2023 | View profile |
| David S. Snyder Chief Financial Officer | ▲ Buy | Open Market | 8,800 Shares held | 11/14/2024 | View profile |
| Fred Grossman Chief Medical Officer | ▲ Buy | Open Market | 2,710 Shares held | 11/11/2024 | View profile |
| Garren Hideki Chief Medical Officer | ▲ Buy | Open Market | 2,000 Shares held | 1/3/2023 | View profile |
Transaction History
| Dov A. Goldstein, MD | ▲ Buy | Option Exercise | 17,557 | $19K | 8/18/2025 |
| David S. Snyder | ▲ Buy | Open Market | 1,800 | $13K | 11/14/2024 |
| Arun Swaminathan | ▲ Buy | Open Market | 5,000 | $37K | 11/13/2024 |
| Fred Grossman | ▲ Buy | Open Market | 2,710 | $20K | 11/11/2024 |
| Arun Swaminathan | ▲ Buy | Open Market | 5,000 | $37K | 11/11/2024 |
| Ann Lee | ▲ Buy | Open Market | 1,000 | $4K | 8/22/2023 |
| Berman Howard | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 |
| Ann Lee | ▼ Sell | Other | 6,479 | $26K | 1/3/2023 |
| Ann Lee | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 |
| Hepner Adrian | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 |
| Garren Hideki | ▲ Buy | Open Market | 2,000 | — | 1/3/2023 |
| David S. Snyder | ▲ Buy | Open Market | 7,000 | — | 1/3/2023 |
| Villalobos Anabella | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 |
| Dov A. Goldstein, MD | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
COYA completes enrollment for Phase 2/3 ALS trial
Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.
COYA completes enrollment for Phase 2/3 ALS trial. Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.